XRAY

Rating neutralAI Memo

DENTSPLY SIRONA

As of 2026-09-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-26 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Delivery against maintained 2026 outlook • 2026-12-31

Base target: $10 / p=50% prob

Biggest risk

The earnings beat did not establish a sales recovery: all three core dental segments contracted, and approximately $44 million of tariff refunds aided Q2 operating cash flow. Guidance was maintained rather than raised. [#8-K-2026-08-06] Company earnings exhibit

Invalidation

Break below $7 or thesis failure.

What would change my mind?

Q2 adjusted EPS of $0.52 exceeded the $0.36 Zacks consensus cited in stored coverage, while free cash flow rose to $55 million from $16 million. Sustained cash generation and stabilization in dental sales could support a rerating. Company earnings exhibit

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-26

Base target

$10

p=50%

Bull target

$14

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Core dental sales remain the downside test
Canadian distribution expansion
Q2 adjusted EPS of $0.52 exceeded the $0.36 Zacks consensus cited in stored coverage, while free cash flow rose to $55 million from $16 million.

BearKey bullets

Execution risk in converting expanded distribution into sales and meeting maintained 2026 guidance.
Persistent contraction in equipment, orthodontic and implant sales.
Tariff costs and the risk that tariff-refund benefits do not recur.

WatchKey bullets

Delivery against maintained 2026 outlook

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $10 (p=50%)

Target spread vs base: +40% / -35%

Scenario probabilities

Bull Target: $14 (p=20%)Base Target: $10 (p=50%)Bear Target: $7 (p=30%)

Commentary

The stored September 8 coverage frames Q2 as an earnings beat with steady guidance but continued dental weakness. A reliable post-print price-reaction series and analyst-revision set were not supplied, so neither is treated as positive evidence. Social, options, short-interest and employee measures are unavailable; the zero fields above denote missing data, not measured neutral readings. The neutral deterministic prior is retained.

As of 2026-09-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Core dental sales remain the downside test
Canadian distribution expansion

Scenarios

Bull Target (Scenario probability)

$14 / p=20% prob

Base Target (Scenario probability)

$10 / p=50% prob

Bear Target (Scenario probability)

$7 / p=30% prob

Analysis 2026-09-26 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Delivery against maintained 2026 outlook
The company maintained 2026 net-sales guidance of $3.5–$3.6 billion and adjusted EPS guidance of $1.40–$1.50. Year-end delivery is a measurable test of whether cash-flow improvement can coexist with weak dental demand. [#8-K-2026-08-06] Company earnings exhibit
Prob 55.00% • Move 8.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Core dental sales remain the downside test
2026-12-31
Q2 sales fell 4.1% reported and 6.3% in constant currency; Orthodontic and Implant Solutions fell 14.9% in constant currency. Continued contraction would weaken the turnaround case. [#8-K-2026-08-06] Company earnings exhibit
Prob 60% • Move -12% • Priced-in 55%

Long-term Catalysts

Months to a year

Canadian distribution expansion
2027-12-31
The expanded Medline Sinclair partnership broadens Canadian access to Connected Technology Solutions, but Q2 segment sales still declined 3.8% in constant currency. Conversion into sustained sales growth remains unproven. [#8-K-2026-08-06] Company earnings exhibit
Prob 45% • Move 15% • Priced-in 30%

Risks

Execution risk in converting expanded distribution into sales and meeting maintained 2026 guidance.
Persistent contraction in equipment, orthodontic and implant sales.
Tariff costs and the risk that tariff-refund benefits do not recur.
Weak volume or mix limiting operating leverage despite improved gross margin.

Peers

Symbol	Summary
ABT	Broad medtech benchmark for margins and cash generation, not a direct dental-products valuation peer.
ALGN	Relevant dental-technology comparison through clear aligners and digital workflows, though narrower than XRAY's portfolio.
NVST	A closer diversified dental-products comparison than broad medtech peers; useful for testing whether XRAY's sales weakness is company-specific.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-26

Loading AI feed…

Symbol

Summary

ABT

Broad medtech benchmark for margins and cash generation, not a direct dental-products valuation peer.

ALGN

Relevant dental-technology comparison through clear aligners and digital workflows, though narrower than XRAY's portfolio.

NVST

A closer diversified dental-products comparison than broad medtech peers; useful for testing whether XRAY's sales weakness is company-specific.